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Abstract: Glaucoma encompasses a wide clinical spectrum of disease, with the common 
pathophysiology of progressive optic neuropathy leading to visual field loss. Elevated intraocular 
pressure (IOP) is a key risk factor in disease progression. Treatment is aimed at reduction of 
IOP to minimize continued optic nerve head damage. Pharmacologic treatment with various 
classes of IOP-lowering medications is generally employed before more aggressive surgical 
interventions. Monotherapy is generally accepted as initial therapy for glaucoma, but at least 
half of patients may require more than one IOP-lowering medication. One option is the fixed 
combination of brinzolamide 1% and timolol maleate 0.5%, which is commercially available in 
some countries as Azarga® for treatment of glaucoma not adequately responsive to monotherapy. 
These agents may also be used in an unfixed fashion, but fixed combination therapy is gener-
ally more convenient for patients, which may result in improved compliance, a reduction of 
the “washout effect” from instilling multiple drops, and a potential reduction in the side effects 
related to multiple doses of preservatives.
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Introduction
Glaucoma is the second leading cause of blindness in the world. It is estimated that 
approximately 60.5 million people suffer from glaucoma. In the United States, it is 
estimated that almost three million people have open-angle glaucoma. By the year 
2020, it is predicted that 11.1 million people will be bilaterally blind from glaucoma 
worldwide.1
Glaucoma is a characteristic optic neuropathy for which the only known modifiable 
risk factor is intraocular pressure (IOP). Other risk factors for progression of open-
angle glaucoma, cannot currently be altered. Therefore, therapeutic options focus on 
controlling the pressure inside the eye.
As with the management of any chronic, asymptomatic disease, challenges exist for 
both the patient and the physician. Treatment for glaucoma is generally chronic and may 
last decades. Even after surgical intervention, further IOP-lowering may be required. 
Patients most often do not notice small or moderate loss of peripheral vision as occurs 
early in the course of the disease, so as with other asymptomatic diseases, convincing 
patients that medications are crucial to preserving their vision can be difficult. Long-
term use of eye drops reduces patient quality of life, and the more drops required, the 
greater the difficulty with and reported worsening of compliance.2 Balancing quality 
of life with the need for medications can be difficult, and any decrease in the number 
of drops may improve that balance.
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Medications may be costly, troublesome to administer, 
and can cause side effects which range from irritating to 
dangerous. In choosing a drug regimen, the patient and 
physician must decide which treatment is most acceptable 
to both parties.
Major classes of medications include beta-blockers, 
alpha-adrenergic agonists, carbonic anhydrase inhibitors, 
and prostaglandin analogs. As more drug classes have 
become available, fixed combinations of these classes 
are being formulated. The fixed combination therapies 
currently available in the United States include dorzolamide-
timolol (Cosopt®, Merck Inc, Whitehouse Station, NJ) and 
brimonidine-timolol (Combigan®, Allergan Inc, Irvine, CA). 
In Europe, fixed combinations of latanoprost-timolol 
(Xalacom®, Pharmacia Inc, New York, NY), travoprost-
timolol (Duotrav®, Alcon Inc, Fort Worth, TX), bimatoprost-
timolol (Ganfort®, Allergan Inc) and brinzolamide-timolol 
(Azarga®, Alcon Inc) are also available. Combination drugs 
may provide benefits of improved patient adherence and 
potential of reduced cost. This article will focus on the fixed 
combination of brinzolamide-timolol.
Pharmacology
There are no published data on the pharmacokinetics 
of the brinzolamide-timolol fixed-dose combination, but 
the pharmacokinetics of each individual drug are known. 
Brinzolamide is a highly specific and reversible carbonic 
anhydrase inhibitor. It targets carbonic anhydrase II, the 
predominant isoenzyme in the ciliary processes. Carbonic 
anhydrase II is also found in many other tissues of the 
body, including the corneal endothelium. The formation of 
bicarbonate ions is blocked by brinzolamide. This prevents 
sodium transport through the ciliary epithelium and results 
in decrease of aqueous humor formation.3
Timolol is a nonselective beta-adrenergic (beta-1 and 
beta-2) receptor antagonist that blocks beta-adrenergic 
receptors in the ciliary body, which leads to a reduction 
of cyclic AMP-dependent aqueous humor formation. Beta 
antagonists were traditionally first-line treatment for IOP, 
but in recent years the prostaglandin analogs have generally 
replaced them as first-line therapy.4
Following ocular administration, systemic absorption 
of both medications does occur. The systemic effects of 
brinzolamide and timolol are discussed in the Safety section 
of this article.
With the issues surrounding patient compliance and 
tolerability of treatment, new and more efficacious modes 
of drug delivery are needed. Contact lenses have been 
developed with high loading and controllable sustained 
release of medication and are being tested for use in vitro.5 
Hydrogels are insoluble, crosslinked polymer network 
structures composed of hydrophilic polymers, which 
have the ability to absorb water and retain their shape 
without dissolving.5 Hydrogel contact lenses imprinted 
with macromolecular memory could provide slow-release 
drug diffusion of glaucoma medications. Success with this 
type of treatment has not yet been demonstrated clinically, 
primarily due to the issue of matching release duration 
with the wear time of the contact lens and maintenance 
of suitable levels of drug concentration.5 Various in vivo 
rabbit studies done recently have demonstrated a prolonged 
therapeutic effect of ophthalmic medications with use of 
hydrogel contact lenses, resulting in a more stable pro-
longed drug level and longer retention time in tear fluid.6–8 
The use of molecularly implanted therapeutic contact 
lenses remains theoretical but holds promise as a future 
treatment option.
Efficacy studies
Brinzolamide and timolol have documented efficacy in 
lowering IOP, as separate medications and in combination. 
Topical carbonic anhydrase inhibitors have been shown to 
reduce IOP by up to 24% when used as monotherapy and 
by an additional 15% when combined with timolol.9 Topical 
beta antagonists have been shown to lower IOP by 19%–29% 
when used as monotherapy.10 Twice or three times daily 
dosing of brinzolamide 1% produces an equally significant 
IOP reduction with no loss of efficacy for up to an 18-month 
period.11,12
Both brinzolamide 1% and dorzolamide 2% added to 
timolol 0.5% reduced IOP significantly compared with timolol 
alone, and both adjunctive treatments showed equivalent 
mean IOP-lowering ability as single agents.13 Various studies 
have evaluated the efficacy of fixed combination therapy. 
In a double-masked, randomized, parallel group, multicenter 
study with a six-month follow-up, a fixed combination of 
brinzolamide 1%/timolol 0.5% was compared with either 
brinzolamide 1% or timolol 0.5%. The fixed combination 
of brinzolamide-timolol reduced IOP by approximately 
8.0–8.7 mmHg from baseline (29.6%–33.5%). For timolol 
0.5% twice daily and brinzolamide 1% twice daily, the 
IOP reduction from baseline ranged from 5.7 to 6.9 mmHg 
(22.8%–26.1%) and 5.1 to 5.6 mmHg (18.9%–20.8%), 
respectively. The fixed combination of brinzolamide-timolol 
0.5% was the most effective at lowering IOP at all visits and 
time points. These results showed that the fixed combination 
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was superior in IOP-lowering efficacy compared with each 
of its individual components.14
A one-year, double-masked, prospective, randomized, 
multicenter, active-controlled, parallel-group clinical trial 
compared the fixed combinations of brinzolamide 1%/
timolol 0.5% and dorzolamide 2%/timolol 0.5%. Mean IOP 
reductions from baseline in the brinzolamide-timolol group 
varied from 7.2 to 9.1 mmHg (reduced 28%–35%) and in the 
dorzolamide-timolol group from 7.4 to 8.9 mmHg (reduced 
by 29%–34%). IOP was reduced to less than 18 mmHg in 
up to 61% of eyes in the brinzolamide-timolol group and 
in up to 59% of eyes in the dorzolamide-timolol group. 
According to this study, the brinzolamide-timolol fixed 
combination demonstrated a significant ability to lower IOP, 
similar to the IOP-lowering ability of dorzolamide-timolol.15 
This observation is logical, since in previous studies, the 
ability of the two carbonic anhydrase inhibitors to lower IOP 
when used alone is equivalent and the other ingredient in the 
combination, ie, timolol 0.5%, is the same.16
Although it appears that no studies have evaluated the 
fixed combination of brinzolamide-timolol when added 
to a prostaglandin analog, three studies have examined 
brinzolamide added to a prostaglandin analog and a 
beta-blocker (two of which used the fixed combination 
of travoprost and timolol). These studies suggest that 
the addition of brinzolamide as a third medication to a 
prostaglandin analog and beta-blocker further reduces IOP 
significantly.17–19
Other factors besides IOP may be influential in the 
pathogenesis of glaucoma and therefore are important to 
consider when evaluating treatment options. Ocular perfusion 
is increasingly recognized as potentially playing a role in the 
disease. In a randomized, crossover, double-masked study 
of 15 patients who underwent evaluation of ocular blood 
flow, confocal scanning laser Doppler flowmetry suggested 
an increase in retinal blood flow with both brinzolamide and 
dorzolamide. Increased oxygen saturation in the retina was 
also measured by photographic retinal oximetry in the supe-
rior and inferior retinal veins with both medications. Color 
Doppler imaging found no significant change in retrobulbar 
blood supply with either medication.20 In a literature review, 
meta-analysis of ocular blood flow and topical carbonic anhy-
drase inhibitors suggests that carbonic anhydrase inhibitors 
increase ocular blood flow velocities and reduce vascular 
resistance in the retinal circulation, specifically in the short 
posterior ciliary and central retinal arteries. More studies are 
needed to evaluate brinzolamide and its hemodynamic effects 
as well as the clinical significance of this finding.21
Safety
Although applied topically, brinzolamide and timolol are 
absorbed systemically.22 While not reported with topical 
use,23 some rare serious reactions can occur with oral carbonic 
anhydrase inhibitors including fulminant hepatic necrosis, 
Stevens–Johnson syndrome, and aplastic anemia.9 Oral 
carbonic anhydrase inhibitors have also caused significant 
systemic side effects due to the renal effects on electrolyte 
balance.9 Systemic adverse effects of the topical carbonic 
anhydrase inhibitors most commonly include a bitter/sour 
taste, headache, dermatitis, allergic reaction, dizziness, dry 
mouth, dyspnea, nausea, chest pain, kidney stones, and 
urticaria.9 Ocular adverse effects include blurred vision, 
keratitis, burning/stinging/discomfort, allergic reaction, blep-
haritis, conjunctivitis, dryness, hyperemia, tearing, pruritus, 
photophobia, conjunctival edema, and discharge.9,23
Carbonic anhydrase II inhibition may affect the main-
tenance of stromal dehydration. In corneas predisposed to 
decompensation, this could cause further loss of corneal 
function and impaired vision. Care should be used in using 
carbonic anhydrase inhibitors in patients with compromised 
corneas, including those with low endothelial cell counts, 
corneal dystrophies, diabetes, or contact lens wearers.22
The beta-adrenergic component, timolol, may cause 
adverse reactions similar to systemic beta-blockers.22 These 
include bradycardia, arrhythmia, cardiac failure, heart 
block, syncope, and bronchospasm. Worsening of mental 
depression, impotence and/or loss of libido, and reduced 
exercise tolerance can also occur.9,24
Additionally, beta-adrenergic blocking agents may mask 
signs of acute hypoglycemia and hyperthyroidism and can 
worsen systemic hypotension. Other contraindications to 
beta-blocker use include a history of bronchial asthma, 
chronic obstructive pulmonary disease, or sinus bradycardia.22 
Beta-adrenoreceptor antagonists may cause ocular side 
effects, such as foreign body sensation, redness, ocular 
burning/stinging, blurred vision, and decreased corneal 
sensation.9,24
The efficacy of topical timolol may be decreased by 
concomitant use of systemic beta-adrenoreceptor antago-
nists, and this may also increase systemic adverse effects.11 
Punctal occlusion and avoiding blinking after placing 
the drop may lessen systemic absorption. Unless neces-
sary, the brinzolamide-timolol fixed combination should 
not be used during pregnancy. Although it is not known 
whether brinzolamide appears in breast milk, timolol does. 
At therapeutic doses, no effects on breastfed infants are   
anticipated.22
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Side effects noted with the brinzolamide-timolol 
fixed combination were similar to those of its individual 
  components. In one study, the most common ocular side 
effect was blurred vision at 3.4% in the brinzolamide-timolol 
combination group compared with 2.9% in the brinzolamide 
group and 0.6% in the timolol group. Other ocular side 
effects in the fixed combination group included irritation/
burning (2.9%), punctate keratitis (1.7%), eye pain (1.1%), 
eye pruritus (1.1%), conjunctival hyperemia (1.1%), foreign 
body sensation (0.6%), corneal epithelium disorder (0.6%), 
and ocular hyperemia (0.6%). The most common nonocular 
adverse effect of the combination brinzolamide-timolol was 
dysgeusia (1.1%), which had a lower occurrence than treat-
ment with brinzolamide alone (4.6%). Additionally, 1.1% had 
a decrease in blood pressure, 0.6% experienced exacerbation 
of chronic obstructive pulmonary disease, and 0.6% had 
pharyngolaryngeal pain.14,25
In another study, the most common adverse ocular 
effects of the fixed combinations of brinzolamide-timolol 
and dorzolamide-timolol were blurred vision, eye pain, 
and irritation. Blurred vision occurred more commonly in 
the brinzolamide-timolol group than in the dorzolamide-
timolol group (3.6% versus 0.5%), thought to be due to the 
suspension formulation. Ocular pain (6.5% compared with 
2.7%) and irritation (10.6% compared with 2.7%) occurred 
more commonly in the dorzolamide-timolol group than in the 
brinzolamide-timolol group. Other ocular reactions included 
foreign body sensation and hyperemia. Dysgeusia was the 
most common nonocular side effect. Overall, the dorzolamide-
timolol group had a significantly greater number of reported 
side effects (23% versus 14.1%),15,16 demonstrating that 
the brinzolamide-timolol fixed combination may be better 
tolerated overall.
Because patient health as well as compliance with 
treatment can be directly affected by tolerability and/or 
adverse effects of medication, it is clearly important to be 
aware of the common reported effects of each medication, 
both as a single agent and in combination.
Patient-focused perspectives
Glaucoma patients face a unique challenge in the management 
of their disease. In contrast with many other ophthalmologic 
diseases, early glaucoma is often asymptomatic and causes 
little or no change in quality of life. In fact, it is often the 
treatment of glaucoma (most commonly in the form of eye 
drops) that negatively affects patient quality of life.
A major difficulty for many glaucoma patients is simply 
getting the drop(s) into their eyes. Most glaucoma patients 
are older and often suffer from debilitative joint disease 
which affects their manual dexterity. Glaucoma patients can 
also have varying degrees of visual disability, ranging from 
decreased contrast sensitivity to low vision from advanced 
loss of peripheral vision. These conditions can affect the 
ability of a patient to administer medication accurately and 
effectively from an eye drop bottle.
Financial issues may also adversely affect compliance. 
However, in one study, the cost of medications was not found 
to be a consistent factor in nonadherence to therapy among 
glaucoma patients.6 Difficulty in affording medication as a 
barrier to compliance may not be detected unless discussed 
directly with the patient.2 In general, patients with more 
advanced disease have higher treatment costs.26
Health literacy has been increasingly recognized as a 
potential barrier to adherence. Health literacy relates to the 
skills needed to read medicine labels and inserts, as well as 
other written health care information. It also includes the 
ability to understand information given by doctors, nurses, 
pharmacists, and other health care staff.27 It has been shown 
that those with poor health literacy are much more likely 
to miss appointments, to miss eye drops, and to refill their 
medications fewer times.27,28
Complicated dosing schedules may also contribute to non-
adherence. Several studies have found that taking multiple 
types of medications and/or taking an increased number of 
doses per day could result in decreased compliance.2
The use of a fixed combination medication could poten-
tially improve compliance with medical therapy and thereby 
improve outcomes. Fixed combination drugs have several 
advantages. They may be more efficacious in lowering IOP 
when combined into one formulation. This also decreases 
long-term preservative exposure and severity of side effects. 
Washout effect from administering one drop after another 
is also eliminated. Fixed combination medications simplify 
dosing by just having one bottle to use (and to refill) and 
they also decrease the frequency of applications. All of these 
factors may have a positive impact on patient compliance 
and IOP control.23,25
Compliance with topical medications is likely linked 
to comfort issues. Multiple studies have demonstrated 
brinzolamide to be more comfortable and preferred by patients 
to dorzolamide, the other major topical carbonic anhydrase 
inhibitor available for treatment of glaucoma.13,17,29–31 In a 
prospective, double-masked, randomized, active-controlled, 
crossover, multicenter study, patients were asked to evaluate 
ocular discomfort associated with the brinzolamide-timolol 
fixed combination versus the dorzolamide-timolol fixed 
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combination. Over 80% in the study expressed a preference 
in medication, and of those, approximately 80% chose 
brinzolamide-timolol, which had significantly lower ocular 
discomfort scores compared with dorzolamide-timolol. 
Brinzolamide-timolol caused more transient blurred vision 
and dorzolamide-timolol had more reported ocular irritation 
and pain. However, it seems patients preferred transient 
blurring of vision over ocular pain or discomfort.16,25,32
In a prospective, double-masked, parallel-group, random-
ized clinical trial, the brinzolamide-timolol group reported 
significantly less ocular discomfort than the dorzolamide-
timolol group after one week. More than three times as many 
patients in the brinzolamide-timolol group reported no ocular 
discomfort after one week of therapy (49% versus 15%). Both 
groups had a statistically significant mean increase in ocular 
discomfort scores from baseline; however, the increase was less 
pronounced in the brinzolamide-timolol group.16,25,33
The more physiologic pH of brinzolamide may be the 
reason for greater ocular comfort,32,33 and this may be true 
of the fixed combination medications as well. Brinzolamide-
timolol has a more physiologic pH of 7.222 as compared 
with 5.6, the more acidic pH of dorzolamide-timolol.34 
Additionally, pH also affects solubility. At physiologic pH and 
room temperature, brinzolamide has a limited solubility, so a 
suspension form is used to maximize delivery.22,25 In contrast, 
dorzolamide and dorzolamide-timolol were formulated as a 
solution with a buffering system using sodium citrate. This 
buffering system could be another explanation for difference 
in comfort. It has also been suggested that the intrinsic 
molecular differences between the fixed combinations may 
account for the reported variation in comfort,33,34 although 
both contain timolol and a carbonic anhydrase inhibitor, so 
the dissimilarity in comfort is not likely to be molecular.32
Therapy with an adjunctive third glaucoma   medication, 
specifically with a prostaglandin analog and a   beta-
blocker (either a fixed combination or monotherapy) with 
brinzolamide added does not appear to elicit any additional 
serious side effects.17–19
Costs
The direct and indirect costs of being afflicted with glau-
coma are difficult to estimate. Studies in the literature have 
focused on the direct costs of glaucoma, namely the cost 
of medications. Indirect costs including lost income due to 
visual disability have been less explored.2,26 Costs associated 
with screening for glaucoma need to be considered as newer 
screening modalities are developed, including possible 
genetic testing for certain types of glaucoma.
Studies looking at the “cost-of-illness” from glaucoma 
found that costs for patients with primary open-angle glaucoma 
were higher than for those with ocular hypertension.26 
Patients with mild and/or controlled primary open-angle 
glaucoma had the lowest costs.26 One European study found 
that medications accounted for about half of total direct 
costs in primary open-angle glaucoma patients, and a French 
study reported that combination therapies were almost twice 
as expensive as monotherapy.26 It is clear that the costs 
of glaucoma are lower when the disease is diagnosed and 
treated early, which suggests that accurate diagnosis and 
early intervention could decrease costs associated with the 
disease.26
Conclusion
The fixed combination of brinzolamide and timolol has been 
shown to be more efficacious than each of its components 
individually and equivalent in efficacy as a fixed combination 
when dosed against the simultaneous administration of 
its two components. It also has a similar safety profile in 
comparison with existing glaucoma medications. The added 
utility of providing two medications in one formula may 
improve patient compliance with the medication. Clinicians 
will need to judge if a fixed combination medication such 
as brinzolamide-timolol is the best choice for their patients, 
because individuals may have varying degrees of tolerability 
and response to the treatment. If an adverse effect is noted, 
the combination drug may need to be discontinued and each 
component individually evaluated. Glaucoma remains a 
disease with extremely diverse manifestations and treatment 
must be tailored to each patient in order to attain the best 
clinical outcome and prevent significant visual loss.
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